Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor – Final Appraisal Determination

In DRAFT guidance, NICE recommends brigatinib as an option for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in adults, only if the company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence